EU nod for Novo’s new fast-acting insulin
European regulators have approved Novo Nordisk’s fast acting insulin Fiasp for the treatment of diabetes in adults, as the bolus component of basal-bolus therapy in combination with basal insulin and for continuous subcutaneous insulin infusion via an insulin pump. Fiasp is an ultra-fast rapid-acting insulin that improves control of postprandial
Continua a leggere